Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
收藏DataCite Commons2026-03-13 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/PR00012840/isLanding
下载链接
链接失效反馈官方服务:
资源简介:
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight.The main purpose is to learn more about how tirzepatide affects body weight.
提供机构:
Vivli
创建时间:
2026-03-13



